Search

Your search keyword '"Wu, Ming-Fang"' showing total 480 results
Start Over Author "Wu, Ming-Fang"
480 results on '"Wu, Ming-Fang"'

2. Clinical practice consensus for the diagnosis and management of melanoma in Taiwan

Author

Wu, Chiao-En, Liao, Yi-Hua, Wu, Cheng-Lin, Yen, Ruoh-Fang, Lin, Chia-Chi, Yang, Muh-Hwa, Yen, Chueh-Chuan, Su, Wu-Chou, Yen, Chia-Jui, Chang, Yi-Fang, Wu, Ming-Fang, Yang, Youngsen, Lin, Chen-Yuan, Yang, Wen-Chi, Wang, Hui-Ching, Li, Cheng-Yuan, Ho, Yin-Yu, Chang, Yao-Yu, Wu, Chieh-Shan, Hsu, Hsiu-Cheng, Chen, Kuang-Hua, Huang, Yenlin, Chen, Chih-Jung, Chuang, Pei-Ju, Lai, Yung-Chi, Huang, Yu-Yi, Tseng, Neng-Chuan, Huang, Yi-Ting, Chu, Chia-Yu, and Wen-Cheng Chang, John

Published
2024
Full Text
View/download PDF

5. Radiomic biomarkers for platinum‐refractory head and neck cancer in the era of immunotherapy

Author

Lu, Hsueh‐Ju, primary, Shen, Chao‐Yu, additional, Chiu, Yu‐Wei, additional, Lin, Wea‐Lung, additional, Peng, Chih‐Yu, additional, Tseng, Hsien‐Chun, additional, Hsin, Chung‐Han, additional, Chuang, Chun‐Yi, additional, Chen, Chun‐Chia, additional, Wu, Ming‐Fang, additional, Huang, Wei‐Shiou, additional, and Shen, Wei‐Chih, additional

Published
2024
Full Text
View/download PDF

16. DNA methylome and transcriptome landscapes of cancer-associated fibroblasts reveal a smoking-associated malignancy index

Author

Su, Sheng-Fang, Ho, Hao, Li, Jia-Hua, Wu, Ming-Fang, Wang, Hsu-Chieh, Yeh, Hsiang-Yuan, Kuo, Shuenn-Wen, Chen, Huei-Wen, Ho, Chao-Chi, and Li, Ker-Chau

Subjects
DNA -- Health aspects, Gene expression -- Research, Genetic research, Methylation -- Research, Smoking -- Health aspects, Lung cancer, Non-small cell -- Genetic aspects -- Risk factors, Fibroblasts -- Genetic aspects -- Health aspects, Health care industry
Abstract

Unlike the better-studied aberrant epigenome in the tumor, the clinicopathologic impact of DNA methylation in the tumor microenvironment (TME), especially the contribution from cancer-associated fibroblasts (CAFs), remains elusive. CAFs exhibit profound patient-to-patient tumorigenic heterogeneity. We asked whether such heterogeneity may be exploited to quantify the level of TME malignancy. We developed a robust and efficient methylome/transcriptome co-analytical system for CAFs and paired normal fibroblasts (NFs) from non-small-cell lung cancer patients. We found 14,781 CpG sites of CAF/NF differential methylation, of which 3,707 sites showed higher methylation changes in ever-smokers than in nonsmokers. Concomitant CAF/NF differential gene expression analysis pointed to a subset of 54 smoking-associated CpG sites with strong methylation-regulated gene expression. A methylation index that summarizes the [beta] values of these CpGs was built for NF/CAF discrimination (MIND) with high sensitivity and specificity. The potential of MIND in detecting premalignancy across individual patients was shown. MIND succeeded in predicting tumor recurrence in multiple lung cancer cohorts without reliance on patient survival data, suggesting that the malignancy level of TME may be effectively graded by this index. Precision TME grading may provide additional pathological information to guide cancer prognosis and open up more options in personalized medicine., Introduction The multistep process of tumor development accompanies the coevolution of the tumor microenvironment (TME) that engages critical participants during tumorigenesis through direct and indirect interaction with tumors (1, 2). [...]

Published
2021
Full Text
View/download PDF

23. In Situ Synthesis of Al-Si-Cu Alloy During Brazing Process and Mechanical Property of Brazing Joint

Author

LONG Wei-min, LU Quan-bin, HE Peng, XUE Song-bai, WU Ming-fang, and XUE Peng

Subjects
Al-Si-Cu brazing filler metal, in situ synthesis, composite brazing wire, braze, Materials of engineering and construction. Mechanics of materials, TA401-492
Abstract

The Al-Si-Cu alloy system is considered to be a promising choice of filler metal for aluminium alloys brazing due to its high strength and low melting point. The greatest obstacle is its lack of plastic forming ability and being difficult to be processed by conventional methods. This disadvantage is ascribed to the considerable amount of brittle CuAl2 intermetallic compound which forms when alloy composition is around the ternary eutectic point. In order to overcome this deficiency, authors of this article proposed to synthesize Al-Si-Cu filler metal by using in situ synthesis method, and the structure and properties of brazing joints were studied. The results show that AlSi alloy is used as the wrap layer, and CuAl alloy is used as the powder core in the composite brazing wire, the two alloys have similar melting points. The machinability of the composite brazing wire is much superior to the traditional Al-Si-Cu filler metal. During the induction brazing of 3A21 alloy, when using AlSi-CuAl composite filler wire, AlSi and CuAl alloys melt almost simultaneously, then after short time holding, Al-Si-Cu braze filler is obtained, the brazing seam has uniform composition and good bonding interface, also, the shearing strength of the brazing joints is higher than the joint brazed by conventional Al-Si-Cu filler metal.

Published
2016
Full Text
View/download PDF

26. Alphanumeric Shape Recognition of Fingertip Writing Trajectory

Author

Wu, Ming-Fang, Li, Jen-Hsing, Wang, Ping-Tsung, Lin, Ruei-Tang, Hutchison, David, Series editor, Kanade, Takeo, Series editor, Kittler, Josef, Series editor, Kleinberg, Jon M., Series editor, Mattern, Friedemann, Series editor, Mitchell, John C., Series editor, Naor, Moni, Series editor, Nierstrasz, Oscar, Series editor, Pandu Rangan, C., Series editor, Steffen, Bernhard, Series editor, Sudan, Madhu, Series editor, Terzopoulos, Demetri, Series editor, Tygar, Doug, Series editor, Vardi, Moshe Y., Series editor, Weikum, Gerhard, Series editor, Goebel, Randy, editor, Siekmann, Jörg, editor, Wahlster, Wolfgang, editor, Pan, Jeng-Shyang, editor, Chen, Shyi-Ming, editor, and Nguyen, Ngoc Thanh, editor

Published
2010
Full Text
View/download PDF

41. EGFR mutation and lobar location of lung adenocarcinoma

Author

Tseng, Chien-Hua, Chen, Kun-Chieh, Hsu, Kuo-Hsuan, Tseng, Jeng-Sen, Ho, Chao-Chi, Hsia, Te-Chun, Su, Kang-Yi, Wu, Ming-Fang, Chiu, Kuo-Liang, Liu, Chien-Ming, Wu, Tzu-Chin, Chen, Hung-Jen, Chen, Hsuan-Yu, Chang, Chi-Sheng, Hsu, Chung-Ping, Hsia, Jiun-Yi, Chuang, Cheng-Yen, Lin, Chin-Hung, Chen, Jeremy J.W., Chen, Kuan-Yu, Liao, Wei-Yu, Shih, Jin-Yuan, Yu, Sung-Liang, Yu, Chong-Jen, Yang, Pan-Chyr, Yang, Tsung-Ying, and Chang, Gee-Chen

Published
2016
Full Text
View/download PDF

46. Endoglin in circulation predicts favourable prognosis for pemetrexed treatment in advanced non-small cell lung cancer

Author

Li, Che-Hsing, Ko, Jiunn-Liang, Hsiao, Yu-Ping, Tsai, Ming-Hung, Lai, Yen-Chein, Hsin, I-Lun, Kang, Yu-Ting, Sheu, Gwo-Tarng, and Wu, Ming-Fang

Subjects
body regions
Abstract

Supplementary Fig. 1. Effects of cathepsin S, matrix metalloproteinase 3 and 9 (MMP3 and MMP9) levels on pemetrexed responsiveness in the cohort. (A) Cathepsin S, (B) MMP3 and (C) MMP9 concentration (ng/mL) in pemetrexed responders and nonresponders measured using ELISA. Progression-free survival of groups with high and low (D) Cathepsin S, (E) MMP3 and (F) MMP9 analysed using the Kaplan–Meier method and the log rank test.

Published
2021
Full Text
View/download PDF

47. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations

Author

Chiu, Chao-Hua, Yang, Cheng-Ta, Shih, Jin-Yuan, Huang, Ming-Shyan, Su, Wu-Chou, Lai, Ruay-Sheng, Wang, Chin-Chou, Hsiao, Shih-Hsin, Lin, Yu-Ching, Ho, Ching-Liang, Hsia, Te-Chun, Wu, Ming-Fang, Lai, Chun-Liang, Lee, Kang-Yun, Lin, Chih-Bin, Yu-Wung Yeh, Diana, Chuang, Chi-Yuan, Chang, Fu-Kang, Tsai, Chun-Ming, Perng, Reury-Perng, and Chih-Hsin Yang, James

Published
2015
Full Text
View/download PDF

49. Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study.

Author

Park, Keunchil, Jӓnne, Pasi A., Kim, Dong‐Wan, Han, Ji‐Youn, Wu, Ming‐Fang, Lee, Jong‐Seok, Kang, Jin‐Hyoung, Lee, Dae Ho, Cho, Byoung Chul, Yu, Chong‐Jen, Pang, Yong Kek, Felip, Enriqueta, Kim, Hyunjin, Baek, Eunhye, Noh, Young Su, Kim, Dong-Wan, Han, Ji-Youn, Wu, Ming-Fang, Lee, Jong-Seok, and Kang, Jin-Hyoung

Subjects
NON-small-cell lung carcinoma, EPIDERMAL growth factor, ERLOTINIB, ANAPLASTIC lymphoma kinase, EPIDERMAL growth factor receptors, KINASE inhibitors, PROTEIN-tyrosine kinases, NON-communicable diseases, LUNG cancer, RESEARCH, CONFIDENCE intervals, GENETIC mutation, HETEROCYCLIC compounds, PROTEIN kinase inhibitors, RESEARCH methodology, LUNG tumors, CELL receptors, MEDICAL cooperation, EVALUATION research, TREATMENT failure, BRAIN tumors, DRUG administration, COMPARATIVE studies, RESEARCH funding
Abstract

Background: In this open-label, international phase 2 study, the authors assessed the efficacy and safety of olmutinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had a confirmed T790M mutation and disease progression on previous epidermal growth factor receptor-tyrosine kinase inhibitor therapy.Methods: Patients aged ≥20 years received once-daily oral olmutinib 800 mg continuously in 21-day cycles. The primary endpoint was the objective response rate (patients who had a confirmed best overall response of a complete or partial response), assessed by central review. Secondary endpoints included the disease control rate, the duration of objective response, progression-free survival, and overall survival. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03).Results: Overall, 162 patients (median age, 63 years; women, >60%) were enrolled from 68 sites in 9 countries. At the time of database cutoff, 23.5% of enrolled patients remained on treatment. The median treatment duration was 6.5 months (range, 0.03-21.68 months). Overall, 46.3% of patients (95% CI, 38.4%-54.3%) had a confirmed objective response (all partial responses). The best overall response (the objective response rate regardless of confirmation) was 51.9% (84 patients; 95% CI, 43.9%-59.8%). The confirmed disease control rate for all patients was 86.4% (95% CI, 80.2%-91.3%). The median duration of objective response was 12.7 months (95% CI, 8.3-15.4 months). Estimated median progression-free survival was 9.4 months (95% CI, 6.9-12.3 months), and estimated median overall survival was 19.7 months (95% CI, 15.1 months to not reached). All patients experienced treatment-emergent adverse events, and 71.6% of patients had grade ≥3 treatment-emergent adverse events.Conclusions: Olmutinib has meaningful clinical activity and a manageable safety profile in patients with T790M-positive non-small cell lung cancer who received previous epidermal growth factor receptor-tyrosine kinase inhibitor therapy. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results